Navigation Links
Vanda Pharmaceuticals Adds Former U.S. Surgeon General, Steven Galson, to its Board of Directors
Date:7/1/2010

ROCKVILLE, Md., July 1 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), announced today that Dr. Steven Galson, former Acting U.S. Surgeon General, has joined Vanda's Board of Directors.  

"I would like to personally welcome Dr. Galson to our Board," said Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer of Vanda.  "We are very fortunate to have a public health physician on our Board as we continue to develop and commercialize important treatments.  Dr. Galson's experience as the former Acting U.S. Surgeon General and Deputy Director and Director of the Center for Drug Evaluation and Research will add tremendous value to the Board," Dr. Polymeropoulos added.

Currently, Dr. Galson is the Senior Vice President for the Civilian Health Operation at Science Applications International Corporation (SAIC).  He has also held executive positions in the U.S. Environmental Protection Agency, U.S. Department of Energy, and the Centers for Disease Control and Prevention's National Institute for Occupational Safety and Health.  Dr. Galson graduated from the State University of New York at Stony Brook where he earned a Bachelor of Science degree in biochemistry.  He later earned a Doctor of Medicine degree from the Mt. Sinai School of Medicine, and a Master of Public Health degree from the Harvard School of Public Health.  A retired rear admiral from the U.S. Public Health Service Commissioned Corps, Dr. Galson is also board certified in general preventive medicine, public health, and occupational medicine.

About Vanda Pharmaceuticals Inc:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders. For more on Vanda, please visit http://www.vandapharma.com.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... and Markets has announced the addition of the "Global Empty Capsules ... their offering. ... Empty Capsules Market is poised to grow at a CAGR of around ... This industry report analyzes the market estimates and forecasts ... presented in the research scope. The study provides historical market data for ...
(Date:2/24/2017)... Research and Markets has announced the addition of ... report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies - 2016, ... The research answers the following questions: ... attributes? How are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)...  In conjunction with DURECT Corporation,s (Nasdaq: ... you are invited to listen to a conference call ... Tuesday, March 14, 2017 at 4:30 pm Eastern Time ... webcast of the presentation will be available by accessing ... Relations."  If you are unable to participate during the ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec discusses ... not if you will be attacked, but when.” However, he and many others involved ... care. , Improvements in auditing and monitoring have taken security in health care a ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... With ProGlass ... Cut Pro X . Users have total control over position, rotation, distortion, edge softness, ... all within Final Cut Pro X. , With ProGlass Prism users are given the ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and ... this year. Dyer started as the Chairman of the Management Committee when IFN ... the corporation including the recruitment of investor/owners and development of the business plan. ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... again hosted their Military Wedding Giveaway, with the winning couple announced on Feb. ... with services generously donated from local vendors: A Matter of Taste, Ryan Rousseau ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to the La Gorce Country Club in Miami Beach to host its ...
Breaking Medicine News(10 mins):